# DERM catalysts: Journey Medical Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/derm/catalysts

> Journey Medical Corp (DERM) has no upcoming catalysts in this calendar. The latest recorded is the Journey Medical Corp earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Journey Medical Corp |
| Ticker | DERM (Nasdaq) |
| SEC CIK | 1867066 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/derm |

## Cash runway

Cash $22.3M as of 2026-09-30; quarterly burn $3.4M; about 19.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-126285).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 28, 2018 | [Qbrexza (glycopyrronium tosylate) FDA approval](https://sec-api.dev/pdufa/glycopyrronium) | DERM |  | completed, approved | "NDA210361 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180628, review_priority STANDARD; sponsor_name JOURNEY; product QBREXZA (GLYCOPYRRONIUM TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210361%22)) |
| October 18, 2019 | [MINOCIN® (minocycline) FDA approval](https://sec-api.dev/pdufa/minocycline) | DERM |  | completed, approved | "NDA212379 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20191018, review_priority STANDARD; sponsor_name JOURNEY; product AMZEEQ (MINOCYCLINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212379%22)) |
| May 28, 2020 | [MINOCIN® (minocycline) FDA approval](https://sec-api.dev/pdufa/minocycline) | DERM |  | completed, approved | "NDA213690 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200528, review_priority STANDARD; sponsor_name JOURNEY; product ZILXI (MINOCYCLINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213690%22)) |
| November 1, 2024 | [Amzeeq® (amzeeq) FDA approval](https://sec-api.dev/pdufa/amzeeq) | DERM |  | completed, approved | "Three of our marketed products, Qbrexza, Amzeeq, and Zilxi as well as Emrosi which was approved by the FDA on November 1, 2024, currently have patent protection." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm)) |
| November 1, 2024 | [MINOCIN® (minocycline) FDA approval](https://sec-api.dev/pdufa/minocycline) | DERM |  | completed, approved | "NDA219015 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20241101, review_priority STANDARD; sponsor_name JOURNEY; product EMROSI (MINOCYCLINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219015%22)) |
| November 4, 2024 | [Emrosi (DFD-29) FDA approval](https://sec-api.dev/pdufa/dfd-29) | DERM | papulopustular rosacea | completed, approved | "Emrosi™ was approved by the FDA in November 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_ex99-1.htm)) |
| November 12, 2024 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/tm2428053d1_ex99-1.htm)) |
| December 31, 2024 | [Journey Medical Corp FDA approval](https://sec-api.dev/companies/derm/catalysts) | DERM | dermatological conditions, today | completed, approved | ""we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_ex99-1.htm)) |
| March 26, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_ex99-1.htm)) |
| May 14, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925048502/tm2514979d1_ex99-1.htm)) |
| June 24, 2025 | [Journey Medical Corp FDA approval](https://sec-api.dev/companies/derm/catalysts) | DERM | dermatological conditions, today | completed, approved | "Corporation (Nasdaq: DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925061956/tm2518699d1_ex99-1.htm)) |
| August 12, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_ex99-1.htm)) |
| November 12, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/tm2530914d1_ex99-1.htm)) |
| Dec 2025 | [Eurax (eurax) FDA approval](https://sec-api.dev/pdufa/eurax) | DERM |  | completed, approved | "In December 2025, the Company received FDA approval for Eurax®, formerly known as the anti-itch product, which was acquired in 2020." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1867066/000110465926126285/derm-20260930x10q.htm)) |
| March 25, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_ex99-1.htm)) |
| May 13, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm)) |
| August 12, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_ex99-1.htm)) |
| November 12, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926126209/tm2629579d1_ex99-1.htm)) |

## Drugs

- [Amzeeq® (amzeeq)](https://sec-api.dev/pdufa/amzeeq): 
- [Emrosi (DFD-29)](https://sec-api.dev/pdufa/dfd-29): inflammatory lesions of rosacea in adults, emrosi, inflammatory lesions of rosacea in adults, inflammatory lesions of rosacea in adults in november 2024, papulopustular rosacea
- [Eurax (eurax)](https://sec-api.dev/pdufa/eurax): 
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium): Asthma
- [MINOCIN® (minocycline)](https://sec-api.dev/pdufa/minocycline): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/derm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DERM catalysts: Journey Medical Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/derm/catalysts

```bibtex
@misc{secapidev_companies_derm_catalysts_20261116,
  title        = {DERM catalysts: Journey Medical Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/derm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_derm_catalysts_20261116","title":"DERM catalysts: Journey Medical Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/derm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
